To externally validate the performance of the International IgA Nephropathy Prediction Tool (IIgANPT) in a Thai cohort with biopsy-proven IgA nephropathy, emphasizing the importance of this validation for clinical application, and to compare the predictive accuracy of model versions with and without the race variable.
Key Findings:
C-statistics were 0.753 (95% CI 0.68–0.82) for the model with race and 0.754 (95% CI 0.69–0.82) for the model without race, indicating statistical significance.
Interpretation:
The IIgANPT demonstrated good discrimination and effective risk stratification in this Thai cohort of patients with biopsy-proven IgAN, with implications for clinical practice. Both model versions performed similarly, indicating limited impact of excluding the race variable in this population.
Limitations:
Calibration point estimates were close to the ideal range but limited by wide confidence intervals, which may affect the reliability of the results. The study conducted in a single tertiary-care center may limit generalizability.
Conclusion:
The IIgANPT is validated for use in Thai patients with IgAN, showing effective risk stratification and discrimination.
Online interest in leucovorin, folate products, and acetaminophen-related autism concerns increased markedly in the 2 weeks following the White House announcement.
